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Abstract
Hepatitis B Virus (HBV) is a type of virus that affects the liver. Chronic hepatitis B is
usually asymptomatic and many HBV carriers remain unaware of their viral status, thereby may
unknowingly transmit the disease. If left untreated or undetected, it could lead to cirrhosis,
hepatocellular carcinoma or mortality. Although this virus is endemic in some parts of the world
such as Asia and Africa, it is important to note that HBV has become a global problem. The
Centers for Disease Control and Prevention (CDC) in conjunction with the United States
Preventive Services Task Force (USPSTF) estimates that about 700,000 to 2.2 million people in
the United States have chronic hepatitis B (CHB) and about 14,000 die yearly as a result of
complications from the virus. Hence, they recommend that screening be offered to individuals at
high risk for hepatitis B virus. People at risk include but are not limited to individuals born in
countries of high HBV endemicity (2%), injection drug users, men who have sex with men,
HIV positive patients, household and sexual contacts of people with HBV, individuals who are
incarcerated, and people infected with hepatitis C virus.
This Doctor of Nursing Practice (DNP) quality improvement project was conducted at the
Order of Malta Clinic in Oakland, California, a safety-net clinic that provides free health care
services to individuals who are uninsured, low income and the working poor in the community.
This clinic serves a huge population of immigrants (about 90% of their patient population)
eligible for chronic hepatitis B screening but based on observations and review of patients’ chart,
it was noted that only about 33% of eligible patients were screened. There is currently no
protocol for chronic hepatitis B screening at this clinic, instead patients are screened based on
presenting symptoms. Hence, this project sought to improve the screening rates for chronic
hepatitis B from 33% to 70% at the Order of Malta clinic using the HBsAg blood test by October
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2019. This was accomplished by interviewing the providers individually and providing in-service
training to physicians and nurse practitioners on the current HBV screening guidelines. A
random retrospective review of patients’ chart was done in order to get a sense of the overall
percentage of eligible patients that were screened. This included a 3-4 weeks of intervention
period and 10 weeks of implementation. After the intervention and implementation, patients’
charts were once again randomly reviewed in order to evaluate the outcome of the project.
The motivation for carrying out this project was to improve the screening rate for chronic
hepatitis B, and treat individuals with a positive result so as to delay or prevent the sequelae that
comes with the virus. The long-term benefit would be to improve overall health and wellbeing,
and also decrease the cost of treating hepatitis B associated complications such as cirrhosis, liver
failure and liver cancer.
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Section II. Introduction
Problem Description
Hepatitis B virus (HBV) is a global health epidemic and a serious health hazard. Hepatitis
is defined as an inflammation of the liver (CDC, 2014). Hepatitis B virus is a kind of virus that
attacks the liver, and could cause both acute and chronic disease, and according to the World
Health Organization, hepatitis B is a life-threatening liver infection caused by the hepatitis B
virus (WHO, 2018). Hepatitis B virus is spread from individuals who are infected to those who
are not immune (Teo & Lok, 2018). This could happen through sharing of needles, sexual
contact, or from mother to baby at birth (CDC, 2015). Teo and Lok (2018) noted that there are
different modes of transmission of HBV but the predominant mode varies in different
geographical locations. In high prevalence areas, mother-child transmission remains the most
predominant mode of transmission while horizontal transmission is predominant in intermediate
areas; unprotected sexual contact and injection drug use are major modes of transmission in low
prevalence areas (Teo & Lok, 2018). Hepatitis B virus has a long incubation period of about 30
to 180 days and an average of 75 days, and it can survive outside of the body for at least 7 days
(WHO, 2018). When hepatitis B virus enters the body, it could be detected within 30 days during
the acute phase, if it persists, it could develop into a chronic phase. It is imperative to note that
acute hepatitis B infection could easily become chronic as it is frequently asymptomatic, and it is
the leading cause of cirrhosis and hepatocellular carcinoma in the United States and globally
(CDC, 2014).
Chronic hepatitis B virus infection, defined as hepatitis B surface antigen (HBsAg)
positivity for at least 6 months, is a major cause of morbidity and mortality worldwide (CDC,
2014). Wilkins, Sams, and Carpenter (2019) defined chronic hepatitis B as the persistence of
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hepatitis B surface antigen for more than six months. They went ahead to state that although
individuals who have chronic hepatitis B are at risk of hepatocellular carcinoma and cirrhosis,
that morbidity and mortality are reduced with adequate treatment (Wilkins et. al, 2019). This also
was supported by the findings of Mitruka et. al (2019), which found that without diagnosis and
treatment, 15–25% of an estimated 240 million persons with chronic hepatitis B infection
worldwide will die prematurely from long term sequelae of cirrhosis, liver failure, and
hepatocellular carcinoma (Mitruka et.al, 2019).
According to the U.S. Preventative Services Task Force, approximately 700,000 to 2.2
million persons in the United States have chronic hepatitis B virus infection (USPSTF, 2014).
An estimated 2 billion people worldwide are infected with HBV and 380 million people are
chronic carriers. There is also a report of 4.5 million new infections and about 620,000 deaths
yearly (Lemoine, Nayagam & Thurz, 2013), this number is markedly increasing by the year. A
more recent data by the World Health Organization showed an estimate of 887,000 HBV related
deaths in 2015 (WHO, 2018). Campbell et.al (2018) stated that between 850,000 and 2,200,000
people in the United States are infected with chronic HBV. Most of these individuals were born
in countries with high HBV prevalence rates which include Asia, Africa, South and Central
America (Campbell, Lopez, Liu, Bhuket & Wong, 2018). Teo and Lok (2018) found that the
overall prevalence of chronic hepatitis B is reported to be 3.6%, however, this number varies
based on the geographical location. The prevalence of chronic HBV ranges from <2% in low
prevalence areas such as the United States, Canada, and Western Europe to 2-7% in intermediate
prevalence areas and 8% in high prevalence areas such as Western Africa (Teo & Lok, 2018).
Even though HBV is highly preventable with the advent of Hepatitis B vaccination or
immunization which remains the most effective means to prevent HBV transmission (Drutz,
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2019), the number of people infected remains high. This clearly points to a gap in screening.
Hence, the U.S. Preventative Services Task Force (USPSTF) recommends screening for chronic
HBV in high risk individuals. “High risk” is defined as immigrants from a country of origin with
a 2% prevalence of chronic HBV, HIV positive patients, intravenous drug users, and previously
incarcerated individuals (USPSTF, 2014).
Geographic Distribution of Chronic Hepatitis B Virus
Hepatitis B virus is found worldwide but differs in endemicity. According to the World
Health Organization (See appendix A and B), most of the world’s population live in countries
where the prevalence of hepatitis B surface antigen (HBsAg) in the general population is high
(≥8%) or intermediate (27%). The prevalence of hepatitis B virus remains low in certain areas
of North America, northern and western Europe, the southern Cone of South America, Australia
and New Zealand (WHO, 2018). The CDC also supports the WHO’s data, which found that
about 45% of the world’s population live in areas of high hepatitis B endemicity where the
prevalence is 8% and a lifetime risk of acquiring it is >60%. Another 43% live in areas of
intermediate endemicity with a prevalence of 2-7% where the lifetime risk of acquiring it is 2060%, and only about 12% of the world’s population live in areas of low endemicity where the
prevalence is <2% with a lifetime risk of <20% (CDC, 2014).
Screening for Chronic Hepatitis B
The most commonly used test for diagnosing acute hepatitis B or detecting carriers is a
blood test, HBsAg. It is the serologic hallmark of hepatitis B virus infection (Lok, 2018). The
presence of HBsAg indicates either an acute or chronic infection (CDC, 2018). In order to screen
for chronic hepatitis B in asymptomatic individuals, hepatitis B surface antigen (HBsAg) and
hepatitis B surface antibody (Anti-HBs) are recommended (Lok, 2018). While HBsAg indicates
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acute or chronic infection, Anti-HBs is a protective antibody that indicates recovery and
immunity against infection (CDC, 2018). For the purposes of this DNP project, only the HBsAg
blood test will be used instead of the USPSTF recommendation of using HBsAg, hepatitis B
surface antibody (Anti-HBs) and Hepatitis B core antigen (Anti-HBc); and this is largely due to
lack of funding from the clinic. The Hepatitis B core antigen (Anti-HBc) will help distinguish
between infection versus immunity, as it only appears after HBV infection and not as a result of
HBV vaccination. Whereas, individuals who have received HBV vaccination have only anti-HBs
(USPSTF, 2014). Testing for HBsAg will target individuals who test positive whereas testing for
Anti-HBs will target individuals who are either immune or susceptible and vaccinate the latter.
Recommendations for future studies will be to test for HBsAg, Anti-HBs and Anti-HBc so as to
vaccinate susceptible individuals to further prevent transmission.
Eligibility Criteria for HBV Screening
The CDC has the following recommendations of persons or groups eligible for screening
for chronic hepatitis B virus. This includes:
persons born in geographic regions with HBsAg prevalence of ≥2%, US born persons not
vaccinated as infants whose parents were born in geographic regions with HBsAg
prevalence of ≥8%, injection-drug users, men who have sex with men, persons with
elevated ALT/AST of unknown etiology, persons with selected medical conditions who
require immunosuppressive therapy, pregnant women, infants born to HBsAg-positive
mothers, household contacts and sex partners of HBV-infected persons, persons who are
the source of blood or body fluids resulting exposures that might warrant post exposure
prophylaxis (e.g., needle stick injury to a health care worker) and persons infected with
HIV (CDC, 2008).
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Clinic Setting
The Order of Malta Clinic in Oakland opened its doors in 2008. It is a nonprofit safetynet primary care clinic that provides free medical care to the uninsured and low-income patients.
It is one of the medical service arms of the Sovereign Order of Malta, Western Association,
U.S.A. The clinic has about 25 volunteer physicians and nurse practitioners, and 35 volunteer
nurses. They offer an array of medical services and specialties including internal medicine,
cardiology, neurology, rheumatology, hematology/oncology, otolaryngology, urology,
gynecology, gastroenterology, podiatry and dermatology (Order of Malta Clinic, 2018). As a
result of the healthcare crisis in the United States, free clinics such as Order of Malta are highly
desired by patients and the communities they serve. A recent study that surveyed over 360 clinics
nationwide found that there is an increase demand and need for free and charitable clinics,
without which, the uninsured population will not have access to preventive medicine (Birs et. al,
2016). This clinic sees a huge number of immigrants mostly from Asia and Africa where the
burden of chronic HBV is endemic. As a safety-net clinic enriched in ethnic minorities, it
provides a great opportunity for screening for chronic hepatitis B virus.
Study Goal
Currently, at the Order of Malta clinic, patients eligible for chronic hepatitis B are not
always screened following the CDC recommendations, instead, this clinic screens symptomatic
patients. Hence, many patients eligible for screening are being missed, and since chronic HBV is
usually asymptomatic, persons with chronic HBV can still transmit the disease to others
unknowingly thereby posing additional threats to the general public. Therefore, the goal of this
project is to improve chronic hepatitis B screening by addressing the gap between current and
optimal screening. By so doing, more patients will be screened and those with a positive HBsAg
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will be treated in order to prevent or delay cirrhosis and hepatocellular carcinoma. Richmond,
Sasadeusz, & Temple-Smith state that if chronic hepatitis B is diagnosed early and managed
appropriately, that the risk of liver disease and hepatocellular carcinoma will be greatly reduced
(2018). For the purposes of this project, we will be screening for chronic HBV using only the
HBsAg test. In Appendix C, some explanations of different types of tests and their
interpretations are provided, but we are only focusing on the HBsAg test due to funding
limitations.
Population, Intervention, Comparison, Outcome and Time (PICOT)
A survey of 277 providers in different healthcare settings organized by the San Francisco
Health Improvement Partnership and Hepatitis B Free Campaign found that HBV screening
remains suboptimal. This was largely attributed to several gaps in providers’ knowledge of
screening guidelines, moreover, a third of the providers were unaware that HBV therapy reduces
the risk for the progression of liver disease (Mukhtar et. al. 2017). Hence, the need to educate
providers as a means to increase knowledge and awareness of hepatitis B, with an expected
outcome of improving HBV screening rates. The PICOT question for this project therefore is:
does provider education/training improve chronic hepatitis B screening compared with no
education within a six months period?
Description of Search Process
In an effort to answer the PICOT question, the following databases were searched:
Cochrane, CINAHL, PUBMED, DynaMed, and PsychINFO using the keywords hepatitis,
hepatitis b, hepatitis b virus, chronic hepatitis b, hepatitis b screening, chronic hepatitis b virus
infection, and hepatitis b prevention. Cochrane database was limited to full text and English
language, it yielded a total of 110 articles. CINAHL database yielded 365 articles but when
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limited to English language and year of publication, 260 articles were identified. DynaMed
yielded 10 articles, and PsychINFO yielded 52 articles. Articles were screened based on their
titles and/or abstracts and the ones that were selected addressed hepatitis b screening, chronic
hepatitis B virus or infection.
Available Knowledge
Barriers to HBV Screening
Two research studies that surveyed 404 Asian-Americans found that barriers to HBV
screening can occur at different levels which include patient, provider, and resource levels
(having insurance and a primary care provider (PCP). Lack of knowledge regarding benefits of
screening was a major patient-related barrier and PCPs not discussing and recommending
screening tests was found to be a huge physician related-barrier to HBV screening. The authors
however, stressed the importance of free screening programs for individuals with no insurance to
facilitate the screening process. They explored some reasons why physicians were not
recommending HBV screening to patients and found two main reasons: lack of knowledge about
HBV and screening guidelines or lack of time. Their recommendation for improving HBV
screening was provider continuing education and the use of electronic health records that has the
capability of highlighting patients’ country of birth in the demographics section. They concluded
that screening for HBV is the most important first step in preventing cirrhosis, liver cancer and
associated mortality (Cheng, Li & Lok, 2016).
Another study that identified barriers to chronic HBV screening found that up to 70% of
chronic HBV carriers were foreign-born immigrants and that about 2 out of every 3 persons
infected with HBV were not aware that they were infected. For this singular reason, Abara,
Qaseem, Schillie, McMahon, and Harris (2017) stressed the importance of screening for HBV as
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a way to decrease chronic HBV health related complications such as cirrhosis and hepatocellular
carcinoma thereby decreasing both direct and indirect healthcare costs, estimated at $1 billion.
Although screening was found to be a very cost-effective method of reducing healthcare cost and
burden, its use still remained low, hence they were of the view that screening for chronic HBV
should be a public health priority. They also identified gaps in screening for HBV in high risk
populations, including the fact that among foreign born persons, screening was 11-67% which is
suboptimal. Despite clinical guidelines from CDC and USPSTF, screening remained low. As
part of their findings, there were barriers that explained why guidelines were not followed. They
identified multiple barriers such as patient-related, physician related and system related barriers.
The authors found that lack of knowledge of chronic HBV, ignorance about screening, language
barrier and cultural differences were some of the barriers noted on patient-related levels.
Clinicians, however, missed the opportunities to screen due to lack of knowledge about clinical
guidelines. Whereas on the system-level barrier, they found that there were very limited hepatitis
funded programs for uninsured patients making screening somewhat difficult. In an effort to
increase HBV screening, they urged clinicians to screen during clinical encounters and
recommended the use of EMR prompts, provider education and standing orders for screening
and vaccination (Abarra, et.al, 2017).
A research study of hepatitis B screening behaviors conducted among Chinese and
Korean Americans found that even though there is a high prevalence rate of HBV among
Chinese and Korean Americans, screening rates remain low at 37% to 55% and 32% to 56%,
respectively. Li et.al (2017) investigated further to learn of the barriers associated with low
screening of HBV, and found that barriers existed at the individual level, system level, and
physician level but the most significant level was the barrier that existed at the physician level.
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Based on this, the authors concluded that a physician screening recommendation significantly
increased screening rates. Hence, they recommended social marketing (aimed at influencing or
changing behaviors) as a way to encourage physicians and healthcare providers to increase their
recommendations of HBV screening (Li et.al, 2017).
A study conducted among Vietnamese-Americans (a population considered to be at high
risk for hepatitis B because they have a high mortality rates of HBV-related liver cancer)
identified barriers that Asian Americans face to HBV screening. These barriers included
personal and cultural related reasons, limited access to healthcare, limited English language
proficiency and a lack of knowledge on the importance of HBV screening. Ma et. al, (2017),
found that adopting a community-based approach would help reduce the stigma associated with
chronic HBV and increase screening rates among this group. Community-based research study
approach would provide education on HBV and reduce the stigma associated with it. Similar to
the findings of other researchers, they also found that patient and provider education would
increase HBV screening (Ma et. al. 2017).
Fears of Deportation and Loss of Privacy
Fear of deportation and loss of privacy were also identified as barriers that prevented
Africans living in the US from seeking HBV screening. Sriphanlop et. al. (2014), noted that lack
of knowledge about HBV and its transmission mode, being asymptomatic and only sought care
when ill, complexity of the U.S. medical system, and the stigma associated with HBV in the
community were some of the barriers that prevented Africans in the U.S. from screening for
HBV. Two unique barriers found among this group that were not found in the Asian-American
community included the issues of privacy or fear of disclosure and fear of deportation if
undocumented and tested positive for HBV. Participants feared that health professionals may
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disclose their HBV status to other community members and family. To increase HBV screening
rate in this population, the authors’ recommendations therefore were to develop a culturally
appropriate intervention to target this group, address the issue of confidentiality and clarify any
misconceptions about deportation in the event of a positive result.
A qualitative study on hepatitis B screening among West African Francophone
immigrants in New York City was conducted. The authors explored barriers hindering this group
from screening for hepatitis B and found that lack of knowledge about HBV screening, the
stigma associated with it, cost, religion, attitudes toward health, undocumented status, and fear of
deportation as major barriers hindering this group. In an effort to increase HBV screening in this
group, they proposed working alongside religious groups and social networks to spread
information on hepatitis B screening, and also specifically addressing the issue of deportation or
detainment (Blanas et.al. 2015).
Increasing Screening Opportunities
Mitruka et. al (2018) conducted a cross-sectional, retrospective analysis and evaluation of
hepatitis B screening among newly arrived refugees at 99 refugee health clinics in 4 states
(California, Washington, Minnesota, and Massachusetts). The main aim of their study was to
improve screening opportunities. They found that among 32,017 persons with valid test results,
4269 were infected with unknown immune status, 937 were infected, 16,481 were susceptible,
and 10,186 were immune, remaining 234 were not categorized. As part of their study, it was
found that the prevalence of hepatitis B infection among refugees was about 10 times higher than
the U.S. general population. These numbers reinforce the importance of early screening and
identification of chronic HBV. Their recommendation was for providers to screen eligible
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individuals, treat infected persons and vaccinate susceptible individuals to further prevent
transmission.
There was also another study that stressed the importance of chronic hepatitis B
screening. The authors were of the view that complications that arise from chronic hepatitis B are
costly to manage, hence the importance of screening in order to identify individuals who are
infected with the virus and at risk of unknowingly transmitting it to others or developing
complications. They went on to opine that treating hepatitis B virus slows its progression to
complications such as cirrhosis and liver cancer. Their recommendation was that in order to be
cost-effective, providers should screen for chronic hepatitis B virus, and treat those who test
positive for the virus (Wright et. al, 2018).
Lack of Trust as Barrier
A group of authors conducted a pilot screening program of hepatitis B screening at an
outpatient endoscopy safety-net hospital. They noted that safety-net hospitals are great places to
screen for chronic hepatitis B virus given the huge number of immigrants that they serve. They
followed the USPSTF recommended guidelines for screening, and their implementation
improved HBV screening from 24.5% to 75.6%. Based on their study, several barriers to
screening were identifiable, including the fact that many minority groups do not trust their
healthcare providers. They also found that most ethnic minorities did not see the need for
screening since they were feeling well and asymptomatic. There was also lack of knowledge
found on both the patients’ side and the providers, the former did not understand the burden of
the disease, mode of transmission and prevention while the latter lacked awareness of the proper
screening for this population, hence the reasons for low screening. Their recommendation
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therefore was that incorporating chronic HBV screening into a safety net clinic would be a great
way to improve screening (Campbell, Lopez, Liu, Bhuket, & Wong 2018).

Rationale
Gap Analysis
This DNP student undertook a random retrospective review of 240 charts at the clinic,
and physicians were interviewed individually to identify the barriers for screening for chronic
HBV. The clinic has noted an increase in the proportion of patients presenting from areas of the
world where the endemic rate of HBV is considered “high” by the CDC, warranting a chronic
HBV screening test. Review of laboratory billing data did not demonstrate an increase in the
rate of HBV screening tests (typically a single blood HBsAg) resulting in concern for underscreening at the clinic. Chart review indicated that a gap in screening exists, the current data so
far indicates about 33% adherence to the screening recommendations per CDC (See Appendix
F).
Theoretical Framework
The health belief model, and the theory of social marketing was used to implement this
project at the Order of Malta Clinic. The health belief model is applicable to the patient
population that the Malta clinic serves and this will be discussed below.
The Health Belief Model:
The health belief model was developed in the 1950s by social psychologists Hochbaum,
Rosenstock and Kegels at the U.S. Public Health Service in an effort to understand the reasons
people fail to respond to disease prevention strategies or screening tests. The authors were of the
view that an individual’s personal belief in either a threat of an illness or effectiveness of
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recommended health behavior would determine if they would adopt that behavior (LaMorte,
2018). There are six concepts of the health belief model: perceived susceptibility, perceived
severity, perceived benefits, perceived barriers, cue to action and self-efficacy.
Perceived susceptibility: personal belief of the risk or vulnerability of acquiring an illness.
Perceived severity: personal belief on the seriousness of an illness and consequences if left
untreated.
Perceived benefits: personal steps available to avoid or cure illness.
Perceived barriers: perceived obstacles to follow recommended health options.
Cue to action: the motivating factor behind accepting a recommended action such as one
experiencing chest pain.
Self-efficacy: personal confidence in one’s ability to perform a behavior.
Jones et al. (2014) stated that in order for people to change behaviors; barriers, benefits
and threats need to be addressed. They went on to summarize the concepts of the health belief
model identified above stating “that people will take action to prevent illness if they regard
themselves as susceptible to a condition (perceived susceptibility), if they believe it would have
potentially serious consequences (perceived severity), if they believe that a particular course of
action available to them would reduce the susceptibility or severity or lead to other positive
outcomes (perceived benefits), and if they perceive few negative attributes related to the health
action (perceived barriers)” (Jones et. al. 2014, p. 569). Based on the literature review, several
cultural and personal beliefs that prevented individuals from HBV screening were identified.
Hence, by adopting this model, and creating awareness of the dangers of chronic hepatitis B, our
patient population might be more willing to adopt it.
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The Theory of Social Marketing:
The theory of social marketing was also found to be applicable to our patient population
at the clinic. Social marketing helps influence health behavior using a wide range of health
communication strategies such as interpersonal communication and message placement at clinics
(Evans, 2006). In this study, the author went ahead to state that social marketing uses behavior,
and persuasion to target health risk behaviors. He identified six stages of social marketing: plan
strategy, selecting communication channels, developing materials, implementation, assessing
effectiveness and feedback (Evans, 2006). Placing messages at the clinic aimed at motivating
patients to ask their healthcare providers of their eligibility for chronic hepatitis B screening
would serve as a social marketing strategy aimed at influencing health behavior.
Specific AIM
By October 2019, about 70% of eligible patients at the Order of Malta Clinic will be
screened for chronic hepatitis B virus using the HBsAg blood test. Education was provided to
physicians and nurse practitioners as a reminder on the CDC eligibility criteria for screening.
Healthcare providers were interviewed individually to gain insights to the barriers of screening
for chronic HBV. There was a random review of 240 patients’ charts, pre-intervention education
was provided and charts were once again reviewed post-intervention to determine the outcome
and success rate.
Section III. Methods
Context
Random retrospective review of 240 charts was undertaken to get a sense of how many
eligible patients were screened prior to the intervention, this represents about 20-25% of the
clinic’s population. A pre-and post-intervention was done to determine the impact of this project
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at the clinic. Guidelines from the CDC, the WHO and existing literature have revealed that
chronic hepatitis B screening among immigrants is low and this was also an issue that was noted
at the clinic. Several meetings were held with the medical director of the clinic and some key
stakeholders. The medium of these meetings included emails, phone calls, and face-face
meetings. An agreement was reached to carry on with the project with the hopes that it will be
beneficial to patients and providers. On the one hand, more patients will be screened for chronic
hepatitis B, and if positive, treatment will be started to prevent or delay end organ damage and
also minimize transmissions. On the other hand, providers’ knowledge on screening guidelines
will improve and thus, they will be more willing and comfortable to recommend chronic
hepatitis B screening to eligible patients.
Intervention
Needs Assessment: A series of interviews with clinic providers on a one-on-one basis was
conducted. This approach was considered over focus groups to ensure that a wide array of
responses could be collected (i.e., Avoiding a group dynamic where an individual’s responses
may be overshadowed by another individual’s presence/contribution). Developing this
instrument was informed by Michie et al’s, twelve domains to consider in designing
interventions to achieve improved implementation (Michie et.. al.,2004). Michie et al’s process
was, at least partially, based on Becker’s Health Belief Model focusing on an aspect of
motivation (e.g., If a person is highly motivated to an action, they will perform the action) and
Ajzen’s Theory of Planned Behavior whereby beliefs affect intention which plays a major role in
carrying out an action (Becker, 1974, Ajzen, 1971).
Potential interview questions that were administered to clinic providers were identified,
vital questions were selected following Fishbein et al’s suggestion that three domains are
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necessary and sufficient for the engagement of a target behavior: intention, lack of environmental
constraints, and the actual skill needed to perform the behavior. The Com-B framework was used
to identify barriers and enablers related to the capability, opportunity, and motivational aspects
of HBV screening (Fishbein et al. 1975). While the interview guide is essential to investigating
the implementation of chronic HBV screening practices, the aim was to further apply the
information gathered toward an intervention to increase HBV screening rates. To that end,
interview questions related to social influences were included, and using the COM-B framework,
social influences from clinic opinion leaders were identified as a major potential enabler of
behavior in the Malta clinic environment (Michie et.al, 2004).
Contextually, 2 clinic opinion leaders that have provided service at the clinic for the longest
time were identified. They were available on the most days (4 out of 5 days that the clinic is open)
and were often sought after for their opinion on patient management both clinically and
logistically/administratively. The process of instrument development is conceptually diagramed in
Appendix K. An interview guide is presented with the construct and domains targeted by each
question and its associated opportunity for change. This tool allows for specific answers to be
elicited following the table-based format with a summary table denoting the provider, overall
themes that arise from the interview, and representative quote(s) following the example in
appendix L.
Educational Intervention: A 30-minute poster presentation was provided to physicians, nurse
practitioners and staff at the clinic. This was done over a course of 3-4 weeks at different times
in order to reach multiple providers. This presentation covered the importance of screening for
chronic HBV, the eligibility criteria and what test to order. Also, healthcare providers were
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provided with a laminated copy of eligibility criteria/screening tool and list of countries of birth
to screen for, as a quick reference guide (see appendix B).
Written Protocol: There was also a written protocol for chronic HBV screening at the Order of
Malta clinic. This written protocol included the screening tool and the test to order for the screening
which in this regard was the HBsAg test.
Policy for Referral: The clinic is willing to treat eligible patients with a positive HBsAg test,
hence, no further referral will be needed at this time. Patients will only be referred for further
treatment if there is an indication of end organ damage or other complications which the clinic
would not be able to manage due to limited funding and resources.
Follow-up: All follow-up will occur at the clinic unless complications arise, which is not
anticipated at this time.
Patient Education: There were visual messages posted in the waiting area at the clinic and in
every examination room on chronic hepatitis B, its risks, and benefits of screening to avoid long
term sequelae. This message was targeted to patients to encourage them to ask their providers
about chronic hepatitis B screening.
Study of the Intervention
The purpose of this project was to improve chronic hepatitis B screening at the Order of
Malta clinic in Oakland, California. The clinic would follow CDC recommendations to screen
eligible patients at the clinic, which for the most part accounts for about 90% of the patients’
population. Eligible patients would be screened regardless of age, gender and family history.
Outcomes Measurement
Outcomes were measured based on the following:
1. The number or percentage of patients screened before and after the intervention.
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2. Increase in screening eligible patients from baseline of roughly 33% to about 70% by
October 2019.
3. Increase in providers’ knowledge of CDC guidelines of chronic hepatitis B screening.
GANTT Chart
The timeline for this project was from December 2018 to December 2019 (see Appendix
G). The GANTT chart provided a visual image of when the project was initiated, the different
stages through the final stage. It also provided an illustration of the clinical coursework that were
completed alongside the completion of this project. The GANTT chart was used to ensure that
this project stayed on track since there are timeframe/timeline for each milestone. The initial plan
for this project was to focus on hepatitis B screening, diagnosis and treatment but after meeting
with the clinic leadership, an agreement was reached to focus only on the screening of chronic
hepatitis B which is what the clinic needs at this time.
Strengths, Weakness, Opportunities, and Threats (SWOT)
A SWOT analysis helped in identifying the strengths, weaknesses, opportunities and both
internal and external threats facing this project. One of the strengths of this project will be cost
saving in the long run because the cost of screening for hepatitis B is far more beneficial than the
cost of treating it. It also provided training opportunities for physicians and nurse practitioners at
the clinic to stay abreast of current CDC recommendations of chronic hepatitis B. This ensured
that providers remained consistent in screening eligible patients for chronic hepatitis B. One
weakness that this project faced was time constraints in trying to provide the different sessions of
the training to providers. There were several opportunities that came with this project. Chronic
hepatitis B screening was improved (although not to the desired goal), thereby enhancing
outcomes. Providers’ knowledge on screening guidelines was also improved, communication
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between providers and patients also improved. One major threat faced in the conduct of this
project was compliance on the part of the providers since change is somewhat difficult to adopt.
A constant reminder was needed in order to ensure that the providers did not fall back to the
status quo. Sustainability was another threat faced in the completion of this project because most
of the providers at the clinic are on a volunteer basis. The question here becomes who continues
to ensure that the CDC guidelines for hepatitis B screening continues to be followed. (See
Appendix J).
Work Breakdown Structure
This project was divided into five different parts (see appendix H). The first part
identified the problems or issues that were addressed. In this case, the first issue was inadequate
screening for chronic hepatitis B and finding ways to improve this screening at the clinic. The
second step involved the identification of key stakeholders. For the purpose of this project, the
stakeholders were physicians, nurse practitioners, patients, nurses and clinic leadership. The third
phase was the planning phase. During the planning phase, training schedules were mapped out,
providers were trained/educated over a 3-4 weeks span on CDC guidelines and
recommendations. There was also a one on one interview of providers to identify barriers to
hepatitis B screening. The fourth stage was the implementation phase. This step was undertaken
over a 2-3 months period in order to provide ample time for providers to incorporate the
screening into their practice and routine. The final phase of this project was the evaluation phase.
The purpose of this stage was to determine whether or not there were positive or negative
outcomes.
Financial Plan
The financial portion of this project is presented below:
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Retrospective review of 240 patients’ charts for 30 hours, this writer’s hourly income
estimated at $60 per hour.



Average time to order hepatitis B screening by physicians and nurse practitioners was
estimated at 15 minutes, hourly pay estimated at $90. Therefore, they spent $22.50 of
their hourly income ordering hepatitis B screening test.



Each hepatitis B surface antigen test (HBsAg) costs $14.20.



Weekly review of charts post-intervention of another 240 charts to evaluate the
outcome/impact of the project was estimated to be 30 hours.



Expense of paper, supplies, ink, lamination and poster was approximately $250.

Profit and Loss
The breakdown of loss associated with this project is provided below:


The writer’s time in data collection, meetings, and training clinic staff:
o $60/hour x 60 hours for pre-and post-chart review = $3,600



Hourly pay for medical staff at the clinic to assist:
o $20/hour x 20 hours = $400
o Cost of paper, lamination, ink, poster and other supplies = $250

Assumed Cost Savings/Avoidance
A key recommendation is to screen eligible patients using the hepatitis B surface antigen
(HBsAg)


The cost of one HBsAg test was $14.20, and the average time to order one test was 15
minutes which resulted in about $22.50 of the providers’ hourly salary.
o 58 HBsAg tests were ordered, 58 x $14.20 = $823.60
o Providers’ time = $22.50 x 58 = $1,305
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Although the economic impact of treating hepatitis B related complications has not been well
studied, an estimate of its annual cost is listed below: (see Appendix Q for more information).


The average cost of treating one case of chronic hepatitis B is estimated at $761,
compensated cirrhosis is $227, decompensated cirrhosis is $11,459, liver transplant is
$86,552, transplant care >12 months following transplant is $12,560, and hepatocellular
carcinoma is $7,533 (Lee, Veenstra, Iloeje, & Sullivan, 2004).

Communication Matrix
As part of this project, stakeholders were identified which include but not limited to
physicians, nurse practitioners, registered nurses, patients, clinic administrator and office staff.
There were several back and forth communication involving this writer and the clinic
administrators, staff, physicians, nurse practitioners, academic supervisor and the second
academic supervisor. Communication took place on an as needed basis via emails, phone calls,
zoom, text messages and face to face meetings. After multiple communication, an area of interest
was identified, and a timeline was developed. The project kicked off after getting an approval
from the agency (see Appendix M). Multiple educational/training sessions on CDC’s guidelines
were presented to providers, clinic administrator and clinic staff (See Appendix P). Laminated
copies of screening tools (see Appendix O) were provided to healthcare providers, and were also
posted in every patient’s room and nursing station for easy reference.
Analysis
Microsoft Excel was used to analyze data collected during this project. Charts and tables
were also utilized to provide clarification on the findings on the data analyzed in this project.
Percentages were used to demonstrate clear and concise results obtained from data collection.
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Ethical Considerations
Some ethical concerns were addressed during the course of this project. Screening for
chronic hepatitis B followed the recommended guidelines as stipulated by the Centers for
Disease Control and Prevention. From a clinical standpoint, clinicians at the clinic did not always
screen for chronic hepatitis B based on the recommendations, individual choices were made to
offer screening if patient had other risk factors. This might have had to do with the fact that
USPSTF rated HBV screening as grade B, indicating that it is recommended to screen only in
high risk individuals. (See Appendix N). For this reason, clinicians often used their personal
judgment to determine which individuals need screening. This, however poses a clinical ethical
concern and in order to address this, clinicians are encouraged to follow the hepatitis B screening
guidelines to screen patients at high risk for chronic hepatitis B. The different grading scale
communicates the importance of a recommended screening to providers (USPSTF, 2018). The
United States Preventive Services Task Force (USPSTF) recommends HBV screening in persons
at high risk. This recommendation is in line with the American Association for the Study of
Liver Diseases (AASLD) and the Center for Disease Control and Prevention (CDC) guidelines
(Mukhtar et.al. 2017).
Another ethical concern that usually arise with a project of this kind is the issue of
privacy but in this case, it was not a concerning factor because patients’ identifiers such as
names, date of birth, and medical record numbers were not used. Country of origin or regions
were used as a major identifier for screening high risk patients.
Jesuit Values and ANA Ethical Standards Ethical Considerations
Hepatitis B screening offered by clinicians would improve patients’ health in the long run
because patients exhibiting positive hepatitis B would be treated and this will avert long term
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damage of hepatitis B. This relates to the American Nurses Association’s ethical standard that
states that “the nurse promotes, advocates for, and protects the rights, health, and safety of the
patient.” (ANA, 2015). This is also in line with the Jesuit values of cura personalis which means
care for the whole person. Cura personalis recognizes an individual as a whole, the body, heart
and soul and promotes the dignity of every person (Otto, 2009). Following the CDC’s guidelines
to screen for chronic hepatitis B would ensure that patients who are eligible for screening are
taken care of, thereby promoting their individual dignity and caring for the whole person.
Section IV. Results
Pre-Intervention Results
A random retrospective review of 240 patients’ charts was undertaken prior to the
intervention, 92 patients were eligible for chronic hepatitis B virus screening, 40 patients were
not eligible and 108 patients had unknown eligibility status. The reason for this high number of
unknown eligibility status was due to inadequate information obtained from patients’ charts. Out
of the 92 patients that were eligible, only 30 patients were screened and this represented
approximately 33% of the patients.
Post-Intervention Results
A post-intervention review of charts was done on a weekly basis to evaluate the effect of
the intervention. Charts of patients who were seen the previous week were reviewed, data
collected and analyzed. Charts were reviewed over 10 weeks and analysis of this data did not
show a significant increase in the screening rate. Another 240 patients’ charts were reviewed,
112 patients were found to be eligible for chronic hepatitis B virus screening, 32 patients were
not eligible and 96 patients had unknown eligibility status. 58 out of 112 eligible patients were
screened and this was approximately 52% of eligible patients. This represented a 19% increase
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from baseline of 33%. Although this project had aimed at improving the screening rate to about
70%, only a 52% increase was noted and this was largely due to certain limitations that will be
discussed in the limitation section.
Follow up Post-Intervention
Extra efforts were made to ensure the success of this project. When it was noted that the
screening was not occurring at the expected rate, some of the nurse volunteers were trained oneto-one on the screening tool on how to determine patients’ eligibility status based on chart
review. The nurse volunteers were encouraged to pull charts of patients who were to be seen the
following day and tagged them for the provider that would be seeing the patient. This extra step
was meant to serve as a reminder for providers to remember to screen eligible patients based on
their eligibility status. This extra effort was not very welcoming as the nurse volunteers already
had so much to accomplish in a given day. Hence, it did not make any significant contribution to
the results of this project.
Section V. Discussion
Summary
The aim of this project was to improve hepatitis B screening rate from baseline of about
33% to about 70% but this aim was not quite achieved, instead the screening rate was only
improved to about 52% which represented a 19% increase. The reason for this minimal level of
achievement on the goal of this project, for the most part may have to do with the uniqueness of
the clinic. The clinic is managed mostly by volunteers, as a result, it was hard to reach all
volunteers. There were some volunteers who only showed up on a monthly basis and others on a
weekly basis. Since it was basically a free clinic, the volunteers were not required to follow any
particular guidelines, hence, individuals chose whether or not to follow the screening
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recommendations for this project. There was also a lot of resistance from providers who
questioned the reason for changing practice especially since more screening would mean more
money to be spent on testing for HBsAg.
Interpretation
There were some in-service trainings provided to both physicians and nurse practitioners
at the clinic in order to expose them to the latest update on chronic hepatitis B screening. One
way to understand the worth of this project was to consider the benefits that early screening
provided to patients. Patients who were screened were satisfied knowing their hepatitis B status.
Early screening would be cost beneficial in the long run because it will save the cost of treating
the sequelae of chronic hepatitis B. This would improve both patients’ and physicians’
satisfaction, and overall quality of life as there will be reduction in mortality and morbidity.
Limitations
Several limitations were identified during the course of this project. This project took
place at a free clinic, as a result, a lot of the patients seen at the clinic had not seen a provider in
so many years, whereas some of these patients had co-morbid and chronic conditions that
required more attention. Hence, chronic hepatitis B screening did not always become a top
priority as a standard of care unless patients had symptoms. Owing to the uniqueness of this
clinic, the findings might not be applicable to other clinics that were structured differently.
Although there was an extra effort made to improve the screening rate as discussed earlier, this
still did not help improve the screening rate because of the uniqueness of this clinic. For instance,
this clinic utilized paper charts, there was no electronic health record making it difficult to flag a
patient’s record as eligible for chronic hepatitis B screening.
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The sample size was also considered as a limitation. A review of 240 charts might not
have been enough to generalize and to conclude that chronic hepatitis B screening had not been
offered to eligible patients. The recommendation would be for future studies to target a larger
audience in order to apply the results to other larger organizations.
Another limitation was the fact that only the HBsAg test was used, instead of the HBsAg,
Anti-HBc and Anti-HBs. As a result, there would be missed opportunities to vaccinate
susceptible individuals against HBV.
Conclusions
Chronic hepatitis B virus remains a global epidemic where some regions of the world are
affected more than others. Even though the United States is not among the highly endemic
regions of hepatitis B, it is imperative to note that owing to the huge number of immigrants in the
States from endemic nations/countries, that approximately 700,000 to 2.2 million persons have
chronic hepatitis B virus (USPSTF, 2014). Since patients with chronic hepatitis B might not
always present with symptoms and will probably transmit the disease unknowingly, screening
therefore is highly recommended in high risk individuals as a way to decrease mortality and the
many sequelae of the virus such as cirrhosis and hepatocellular carcinoma. The Order of Malta
clinic sees a huge number of immigrants (about 90% of their patient population), hence,
incorporating chronic hepatitis B screening as part of routine care for eligible patients is highly
encouraged. The screening will help to identify chronic carriers of hepatitis B virus, including
offering them treatment to decrease or prevent the long-term sequelae of the virus.
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Section VI. Other Information
Funding/Cost
Each HbsAg test costs $14.20 and the clinic leadership covered the cost of this test for
eligible patients at the clinic who met the screening criteria. No other outside sources supported
this project.
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Appendix A
Geographic Distribution of Chronic HBV Infection
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Appendix B
Geographic Regions with a Prevalence of Hepatitis B Surface Antigen >2% (USPSTF)
Region

Countries

Africa

All

Asia

All

Australia and South Pacific

All except Australia and New Zealand

Middle East

All except Cyprus and Israel

Eastern Europe

Malta, Spain, and indigenous populations in
Greenland

North America

Alaska natives and indigenous populations in
northern Canada

Mexico and Central America

Guatemala and Honduras

South America

Ecuador, Guyana, Suriname, Venezuela, and
Amazonian areas of Bolivia, Brazil,
Colombia, and Peru

Caribbean

Antigua and Barbuda, Dominica, Grenada,
Haiti, Jamaica, St. Kitts and Nevis, St. Lucia,
and Turks and Caicos Islands
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Appendix C
Hepatitis B Serologic Marker Interpretation (CDC 2014)
Total anti-HBc

IgM anti-HBc

Anti-HBs

(Antibody to

(Immunoglobulin

(Antibody to

hepatitis B core

M to anti-HBc)

HbsAg)

-

-

Interpretation

HbsAg
(Hepatitis B surface
antigen)
antigen)
-

-

Never infected and
susceptible to infection

+

+

-

-

Chronic infection

-

+

-

+

Recovered from past
infection and immune

+

+

+

-

Acute infection

-

+

-

+

Immune by natural
infection

-

-

-

+

Immune by hepatitis B
vaccination

-

+

-

-

Immune by natural
infection or possible
false positive
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Appendix D
DNP Statement of Non-Research Determination Form
Title of Project:
Improving Chronic Hepatitis B Virus Screening at a Safety-Net Primary Care Clinic
Brief Description of Project:
Currently, at the Order of Malta clinic, patients eligible for chronic hepatitis B are
not always screened following the CDC recommendations; this clinic screens
symptomatic patients. Hence, a lot of patients eligible for screening are being missed, and
since chronic HBV is usually asymptomatic, persons with chronic HBV can still transmit
the disease to others unknowingly thereby posing additional threat to the general public.
Therefore, the goal of this project is to improve chronic hepatitis B screening thereby
addressing the gap between current and optimal screening. By so doing, more patients
will be screened and those with a positive HBsAg will be treated in order to prevent or
delay cirrhosis and hepatocellular carcinoma. Richmond, Sasadeusz, & Temple-Smith
state that if chronic hepatitis B is diagnosed early and managed appropriately, that the
risk of liver disease and hepatocellular carcinoma will be greatly reduced (2018). For the
purposes of this project, we will be screening for chronic HBV using only the HBsAg
blood test.
D) Aim Statement:
By October 2019, about 70% of eligible patients at the Order of Malta Clinic will
be screened for chronic hepatitis B virus using the HbsAg blood test. Education was
provided to physicians and nurse practitioners as a reminder on the CDC eligibility
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criteria for screening. Healthcare providers were interviewed individually to gain insights
to the barriers of screening for chronic HBV. 240 patients’ charts were randomly
reviewed; pre-intervention education was provided and charts were once again reviewed
post-intervention to determine the outcome and success rate.
B) Description of Intervention:
A 30 minutes poster presentation was provided to physicians, nurse practitioners and staff
at the clinic. This was done over a course of 3-4 weeks at different times in order to reach
multiple providers. This presentation covered the importance of screening for chronic
HBV, the eligibility criteria and what test to order. Also, healthcare providers were
provided with a laminated copy of eligibility criteria/screening tool and list of countries
of birth to screen for, as a quick reference guide (see appendix B).
C) How will this intervention change practice?
It will provide consistency among providers. By following the recommended screening
guidelines of chronic hepatitis B virus, patients who are positive will be treated to avert
or prevent the long-term complications of the virus and also prevent transmission to
unaffected individuals. This will reduce health care cost in the long run and improve
overall quality of life.
D) Outcome measurements:
Outcomes were measured based on the following:
1. The number or percentage of patients screened before and after the intervention.
2. Increase in screening eligible patients from baseline of roughly 33% to about 70%
by October 2019.
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3. Increase in providers’ knowledge of CDC guidelines of chronic hepatitis B
screening.
References:
Richmond, J. A., Sasadeusz, J., & Temple-Smith, M. (2017). The Role of Primary Health
Care in Hepatitis B Testing and Management: A Case Study. Journal of community
health, 43(1), 38-47.
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767201/

To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the
criteria outlined in federal guidelines will be used: (http://answers.hhs.gov/ohrp/categories/1569)

☐ X This project meets the guidelines for an Evidence-based Change in Practice Project as
outlined in the Project Checklist (attached). Student may proceed with implementation.

☐This project involves research with human subjects and must be submitted for IRB approval
before project activity can commence.
Comments:
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST *
Instructions: Answer YES or NO to each of the following statements:
Project Title: Improving Chronic Hepatitis B Virus Screening at a Safety-

YES

Net Primary Care Clinic
The aim of the project is to improve the process or delivery of care with
established/ accepted standards, or to implement evidence-based change. There is
no intention of using the data for research purposes.
The specific aim is to improve performance on a specific service or program and is
a part of usual care. ALL participants will receive standard of care.
The project is NOT designed to follow a research design, e.g., hypothesis testing
or group comparison, randomization, control groups, prospective comparison
groups, cross-sectional, case control). The project does NOT follow a protocol that
overrides clinical decision-making.
The project involves implementation of established and tested quality standards
and/or systematic monitoring, assessment or evaluation of the organization to
ensure that existing quality standards are being met. The project does NOT
develop paradigms or untested methods or new untested standards.

X

X
X

X

NO
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The project involves implementation of care practices and interventions that are
consensus-based or evidence-based. The project does NOT seek to test an
intervention that is beyond current science and experience.
The project is conducted by staff where the project will take place and involves
staff who are working at an agency that has an agreement with USF SONHP.
The project has NO funding from federal agencies or research-focused
organizations and is not receiving funding for implementation research.
The agency or clinical practice unit agrees that this is a project that will be
implemented to improve the process or delivery of care, i.e., not a personal
research project that is dependent upon the voluntary participation of colleagues,
students and/ or patients.
If there is an intent to, or possibility of publishing your work, you and supervising
faculty and the agency oversight committee are comfortable with the following
statement in your methods section: “This project was undertaken as an Evidencebased change of practice project at X hospital or agency and as such was not
formally supervised by the Institutional Review Board.”
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X

X
X
X

X

ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an
Evidence-based activity that does NOT meet the definition of research. IRB review is not
required. Keep a copy of this checklist in your files. If the answer to ANY of these questions
is NO, you must submit for IRB approval.
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human
Research Committee, Partners Health System, Boston, MA.

STUDENT NAME (Please print): Uwaezu Joy Umeh
Signature of Student:
______________________________________________________DATE____________

SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):
Dr. Jo Loomis______________________________________________
Signature of Supervising Faculty Member (Chair):
______________________________________________________DATE____________

CHRONIC HEPATITIS B SCREENING

49
Appendix E

Evaluation Table
Citation: Author(s),
Date of publication
& Title

Design/Method

Study Findings

Appraisal

Cheng, S., Li, E., &
Lok, A. S. (2016).
Predictors and
Barriers to Hepatitis
B Screening in a
Midwest Surburban
Asian Population.
Abara WE, Qaseem
A, Schillie S,
McMahon BJ, Harris
A.M. (2017).
Hepatitis B
Vaccination,
Screening, and
Linkage to Care:
Best Practice Advice
From the American
College of
Physicians and the
Centers for Disease
Control and
Prevention.
Li, S., Sim, S-C.,
Lee, L., Pollack,
H.J., Wyatt, L.C.,
Trinh-Shevrin, C.,
Pong, P., & Kwon,
S.C. (2017).
Hepatitis B
Screening and
Vaccination
Behaviors in a
Community-Based
Sample and Chinese
and Korean
Americans in New
York City
Ma, G.X., Fang,
C.Y., Seals, B.,
Feng, Z., Tan, Y.,
Siu, P., Yeh, M. C.,
Golub, S.A.,

Survey studies
of 404
participants

Screening for HBV is the most
important first step in preventing
cirrhosis, liver cancer and mortality.

Level IIIA

Systematic
reviews, metaanalyses, and
randomized and
nonrandomized
intervention
studies from the
research
literature.

Screening in high-risk populations is
the first step in identifying persons
with chronic HBV infection, thereby
reducing the burden and cost
associated with HBV infection.

Level IIIA

Survey study,
cross sectional
design study

HBV screening rates are low among
Chinese and Korean Americans but
physician’s screening
recommendation significantly
increased screening rates.

Level IIIA

Cluster
communitybased
randomized trial

There is a high prevalence of
hepatitis b among Vietnamese
Americans yet screening remained
low and this could be attributed to
lack of knowledge of HBV, personal

Level IA
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Nguyen, M.T., Tran,
T., Wang, M.
(2017).
A CommunityBased Randomized
Trial of Hepatitis B
Screening Among
High-Risk
Vietnamese
Americans
Sriphanlop, P.,
Jandorf, L., Kairouz,
C., Thelemaque, L.,
Shankar, H., &
Perumalswami, P.
(2014). Factors
Related to Hepatitis
B Screening among
Africans in New
York City
Blanas, D., Nichols,
K., Bekele, M.,
Shankar H., Bekele,
S., Jandorf, L.,
Izzeldin, S., Ndiaye,
D., Traore, A.,
Bassam, M.,
Perumalswami, P.
(2015). Adapting the
Andersen Model to a
Francophone West
African Immigrant
Population: Hepatitis
B Screening and
Linkage to Care in
New York City
Mitruka et al., 2018

Wright, C.M.,
Boudarene, L., Ha,
N.T., Wu, O.,
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and cultural reasons but a
community-based approach to
screening, patient and provider
education would help increase
screening.

Qualitative study

Lack of knowledge of HBV and
Level IIIA
transmission mode, privacy, fear of
disclosure and deportation if positive
for HBV on screening were found to
be some of the barriers preventing
Africans in the U.S. from screening
for HBV.

Qualitative study

Religion, attitudes toward health,
undocumented status, and fear of
deportation were barriers to
screening for HBV among West
African Francophone immigrants

Level IIIA

Cross-sectional,
retrospective
analysis

They found that among 32,017
persons with valid test results, 4269
were infected with unknown
immune status, 937 were infected,
16,481 were susceptible, and 10,186
were immune, remaining 234 were
not categorized. Their study found
that the prevalence of hepatitis b
infection among refugees was about
10 times higher than the U.S.
general population.

Level IIIA

A systematic
review and
literature search

The authors found that screening
for chronic hepatitis B is costeffective, and that treatment

Level IA
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Hawkins, N. (2018).
A Systematic
Review of Hepatitis
B Screening
Economic
Evaluations in Lowand Middle-Income
Countries

Campbell, B.,
Lopez, A., Liu, B.,
Bhuket, T., & Wong,
R.J. (2018). A Pilot
Program Integrating
Hepatitis B Virus
(HBV) Screening
into an Outpatient
Endoscopy Unit
Improves HBV
Screening Among an
Ethnically Diverse
Safety-Net Hospital.

of databases
such as
MEDLINE,
PubMed,
EMBASE,
CINAHL, the
Cochrane
Library,
EconLit, and
Global Health
A pilot study,
randomized
controlled trial
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reduces hepatitis associated
complications

They identified barriers to
screening for hepatitis b such as
mistrust of providers by minority
groups, lack of knowledge of
HBV screening. This pilot study
showed that HBV screening rates
could be improved at safety-net
clinics.
Their recommendations therefore
were that incorporating chronic
HBV screening into a safety net
clinic would be a great way to
improve screening.

Level II B
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Appendix F
Gap Analysis

Gap Analysis

Restrospective review of charts
Individual interviews with MDs
and NPs
Review of laboratory
billing data

Low screening of chronic hepatitis B:
Preliminary estimates suggest 3040% of eligible patients are screened
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Appendix G

GANTT Chart

GANTT CHART

2018

Stages of Project
and DNP Course
Work
Stage I:
-Needs Assessment
-Protocol
Development
-Literature Review
-Identification of
Stakeholders
-NURS 7005
Project
Management
Stage II:
-Chart Review
-Data Collection
-NURS 785
Practicum IV
-NURS 749B
Prospectus
Development
Stage III:
-Project
Implementation
-NURS 763
Financial
Management
-NURS 789 DNP
Project
NURS 795 DNP
Implementation
Stage IV:
-Project Draft
-Final Project
Submission

Dec

2019
Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec
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Appendix H

Work Breakdown Structure

Problem

Stakeholders

Physicians
Low hepatitis B
screening rate at
the Order of Malta
Clinic

Planning

Implementation

Map out training
sessions/schedules

Teaching/Education
sessions

Interview providers
one to one

Written Hepatitis B
protocol

Set budget

Laminated hepatitis
B screening
guidelines

Evaluation

Nurse Practitioners

Nurses

Patients

Clinic leadership

Chart review to
determine
compliance and
measure outcome
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Appendix I

Responsibility/Communication Matrix

What
Meeting with
academic advisor and
committee member,
Dr. Loomis and Dr.
Rowniak
Meeting with Clinic
supervisors,
administrator, and
Director to discuss
the project, staffing,
and schedules
Chart review with
volunteer staff

When
As needed

To whom
Advisor

How
Email, zoom sessions

Monthly and as
needed

Clinic supervisors,
clinic director

Email, face-to-face
meeting, text
message

As needed

Volunteer staff

Face-to-face
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Appendix J

SWOT Analysis

• overall cost saving
• consistency in following guidelines
• Training opportunities for
providers
• Improve overall quality of life

•Improvement of chronic hepatitis B
screening
•Improved knowledge of hepatitis B
screening guidelines
•Enhanced communiation between
providers and patients
• To start treatment early if HBsAg
positive

• Time consuming
• Missed opportunities to vaccinate
susceptibe individuals since HBsAb
will not be tested
• sample size

Strength

Weakness

Opportunities

Threats
•Resistance to change
•compliance
•sustainability
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Appendix K

Data Collection Instrument

12 Theoretical Domain Michie et al.
2004

Health
Belief
Model

Knowledge
Theory of
Planned
Behavior

Intention
Environment

COMB*

Data
Collection
Instrument
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Appendix L
CQI Method/Data Collection Tool
Interview Question by Domain (Fishbein et al. 1991)
Knowledge:
How familiar are you with HBV screening
eligibility requirements?

Construct (Michie et al. 2005)
- Knowledge: provider/intake nurse
screening eligibility knowledge following
clinic guidelines

Do you know what tests to order for
someone who is eligible?

- Knowledge about scientific rationale:
provider/intake nurse understanding of
HBV prevalence, transmission, and
potential for chronic infection; knowledge
regarding chronic HBV potential
complications; knowledge of decrease risk
from HBV vaccination

What is the rate of screening done at the
clinic? (in terms of test per eligible patient)
What is the rate of chronic HBV infection
identified at the clinic?
Do you typically know the prevalence of
HBV infection in your patients’ home
countries? (including the Bay Area/United
States)
How do you think HBV screening can be
important to patients and to our clinic/local
community/beyond?

- Schemas + mindsets + illness
representations: HBV infection
representation (wide array), clinic
population diversity (eg. last month 40% of
patients presented from a country of origin
in sub-Saharan Africa, where the prevalence
of HBV is considered “high” by the CDC,
warranting HBV screening)
- Procedural Knowledge: screening process
knowledge (how to order, which form to
order, which test to order (HbsAg - blood),
reporting of test results from lab to clinic

Intention:
Do you feel that you need to assess HBV
screening eligibility for every patient? Why
or why not?
Would you say there is a difference in
assessment rate between patients with
specific chief complaints and those
presenting for health maintenance/follow-up?

- Intention: providers intend to provide
underrepresented populations with optimal
health care
- Goal priority: provider goals (do they
include preventative medicine/long term
health management?)
- Intrinsic motivation: provider’s natural
stance towards HBV screening at clinic

Does assessing HBV screening eligibility
interfere with other goals of yours? How
much more time/resources would be needed
to include HBV screening?
Skill:
Do you know which form/where on the form
to order the test?

- Skills: assess patient eligibility,
recommend screening (interpersonal
communication), ordering correct labs

Do you have patients who refuse HBV
screening? If so, do you know why?

- Competence: competence in assessing
eligibility, recommending screening,
ordering labs

Summary of Mock Data
“I’m vaguely familiar insofar as knowing
whether the majority of my patients are
eligible/ineligible.”
“I know the HBsAg is the usual test, but I’m
not sure when the other blood tests should
be used”
“I have no idea about the rate of the clinic’s
screening, but I know I probably underscreen”
“I know the HBV prevalence is high in
Eritrea, but otherwise I’m not completely
sure”
“HBV screening is likely vital for our
foreign patients who are visiting the country
temporarily. I’m unsure of the local
impact”
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How do you go about addressing screening
on a busy day vs. a non-busy day?
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- Interpersonal skills: ability to
communicate HBV screening
recommendation rationale

How difficult is it to develop a screening
eligibility assessment routine?
Do you have any reminders regarding
screening/other preventative medicine
recommended screening?
Environmental Constraints:
To what extent do physical or resource
factors facilitate or impede the assessment of
eligibility?
Are there tasks competing with the
assessment of eligibility?
How often is time a concern when it comes
to screening assessment? For cases where
the visit does not have enough time, how
often is that a great deal of time? (>20
minutes) For cases where the visit has
already gone over time, how much time is
usually gone-over?
Do you have the necessary resources to
assess eligibility in all your patient
interviews?
Social Influences:
Do you feel like you have the support system
to conduct screening eligibility assessment at
each encounter?
How often do you consult other
physicians/resources per day (or other unit of
time/resource)?
Did you observe others evaluating screening
eligibility?
What is the overall climate of the clinic in
regard to HBV screening?

- Resources/material resources: availability
and management of resources related to
screening (eg. availability of eligibility
criteria, availability of other providers who
can consult, availability of screening test
forms)
- Environmental stressors: environmental
stressors perceived to influence screening
assessment
- Person x environment interaction: the
interaction between the providers and the
environment (eg. patients who have left
work to make an appointment, patients with
a history of failure to follow-up, patients
with difficulty acquiring transportation)

- Social support: whether providers have the
social support from clinic
administrative/opinion leaders to support
the assessment.
- Leadership: the degree to which opinion
leaders/ providers hold in high esteem
influence their performance of eligibility
assessment
- Organizational climate: the clinic’s overall
attitude regarding HBV screening and
whether it has the necessary tools/resources
to facilitate screening for every patient

- Learning/modeling: whether someone
influential helps model the target behavior
and influences providers in administration
of screening eligibility at every patient
encounter
Mock Data Summary Example: (to be placed above the answers above)
Provider
Key Domains
Overall theme(s)
Representative quote(s)
Engaged
Jane Doe, MD
Environmental
Provider often finds their
“I just don’t have the time to focus on other issues sometimes. I do
context
patient encounters going
make a note of it and recommend the next provider assess for health
over time focused on other
care maintenance concerns including HTN, DM, and other
health concerns.
screening”
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Questions:
How familiar are you with HBV screening eligibility
requirements?
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Responses
Vaguely familiar insofar as knowing whether the majority of my
patients are eligible/ineligible.
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Appendix N: USPSTF Grade Definitions:
Grade

A
B
C
D
I
Statement

Definition

Suggestions for Practice

The USPSTF recommends the service. There is high certainty
that the net benefit is substantial.

Offer or provide this service.

The USPSTF recommends the service. There is high certainty
that the net benefit is moderate or there is moderate certainty
that the net benefit is moderate to substantial.

Offer or provide this service.

The USPSTF recommends selectively offering or providing
this service to individual patients based on professional
judgment and patient preferences. There is at least moderate
certainty that the net benefit is small.

Offer or provide this service for selected patients
depending on individual circumstances.

The USPSTF recommends against the service. There is
moderate or high certainty that the service has no net benefit
or that the harms outweigh the benefits.

Discourage the use of this service.

The USPSTF concludes that the current evidence is
insufficient to assess the balance of benefits and harms of the
service. Evidence is lacking, of poor quality, or conflicting, and
the balance of benefits and harms cannot be determined.

Read the clinical considerations section of USPSTF
Recommendation Statement. If the service is offered,
patients should understand the uncertainty about the
balance of benefits and harms.
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Appendix O: Screening tool; CDC’s Recommendation for Routine Testing and Follow-up for Chronic
Hepatitis B Virus Infection
Population
Testing
Vaccination/Follw-up
Persons born in regions of high and
Test for HBsAg, regardless of
If HBsAg-positive, refer for medical
intermediate HBV endemicity (HBsAg vaccination status in their country
management. If negative, assess for onof origin, including immigrants,
going risk for hepatitis B and vaccinate if
prevalence 2%)
refugees, asylum seekers and
indicated
internationally adopted children
US born persons not vaccinated as
Test for HBsAg regardless of
If HBsAg-positive, refer for medical
infants whose parents were born in
maternal HBsAg status if not
management. If negative, assess for onregions with high HBV endemicity
vaccinated as infants in the United
going risk for hepatitis B and vaccinate if
States
indicated
(8%)
Injection-drug users
Test for HBsAg, as well as anti1st vaccine dose should be given same
HBc or anti-HBs to identify
visit as testing. Susceptible persons
susceptible persons
should complete a 3-dose hepatitis B
vaccine series
Men who have sex with men
Test for HBsAg, as well as anti1st vaccine dose should be given same
HBc or anti-HBs to identify
visit as testing. Susceptible persons
susceptible persons
should complete a 3-dose hepatitis B
vaccine series
Persons needing immunosuppressive
Test for all markers of HBV
Treat persons who are HBsAg-positive.
therapy, including chemotherapy,
infection (HBsAg, anti-HBc, and
Monitor closely persons who are antiimmunosuppression related to organ
anti-HBs)
HBc positive for signs of liver disease
transplantation, and
immunosuppression for rheumatologic
or gastroenterologic disorders
Persons with elevated ALT/AST of
Test for HBsAg along with other
Follow up as indicated
unknown etiology
appropriate medical evaluation
Donors of blood, plasma, organs,
tissues, or semen

Test for HBsAg, anti-HBc, and
HBV-DNA as required

Hemodialysis patients

Test for all markers of HBV
infection (HBsAg, anti-HBc, and
anti-HBs)
Test for HBsAg during each
pregnancy, preferably in the 1st
trimester.
Test at the time of admission for
delivery if prenatal HBsAg test
result is not available of if mother
was at risk for infection during
pregnancy
Test for HBsAg and anti-HBs 1-2
months after completion of at least
3 doses of a licensed hepatitis B
vaccine series (ie., at age 9-18
months, generally at the next wellchild visit to assess effectiveness of
post-exposure
immunoprophylaxis). Testing
should not be performed before age

All pregnant women

Infants born to HBsAg positive
mothers

Vaccinate against hepatitis B and
revaccinate when serum anti-HBs titer
falls below 10mIU/m
If HBsAg positive, refer for medical
management. To prevent perinatal
transmission, infants of HBsAg-positive
mothers and unknown HBsAg status
mothers should receive vaccination and
post-exposure immunoprophylaxis in
accordance with recommendations and
within 12 hours of delivery
Vaccination in accordance with
recommendations

CHRONIC HEPATITIS B SCREENING

64
9 months or within 1 month of the
most recent vaccine dose

Household, needle-sharing, or sex
contacts of persons known to be
HBsAg positive

Test for HBsAg, as well as antiHBc or anti-HBs to identify
susceptible persons

Persons who are the sources of blood
or body fluids resulting in an exposure
(e.g., needlestick, sexual assault) that
might require post-exposure
prophylaxis

Test source for HBsAg

HIV-positive persons

Test for HBsAg, as well as antiHBc or anti-HBs to identify
susceptible persons

1st vaccine dose should be given same
visit as testing. Susceptible persons
should complete a 3-dose hepatitis B
vaccine series
Vaccinate healthcare and public safety
workers with reasonably anticipated
occupational exposures to blood or
infectious body fluids. Provide postexposure prophylaxis to exposed person if
needed
Vaccinate susceptible persons against
hepatitis B
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Appendix Q: Proforma
Chronic Hepatitis B Project
Year 1
Year 2
Year 3
$14.20
$15.90
$17.30
Cost of HBsAg(a)
$22.50
24.33
$26.98
Average time spent
to order HBsAg (a)
$250.00
$320
$410
Supplies(b&c)
Cost of treating
$761
$849
$950
chronic hepatitis B (a)
Cost of treating
$227
$372
$428
compensated cirrhosis
(b)
Cost of treating
$11,459
$13,238
$15,874
decompensated
cirrhosis (b)
Cost of treating
$7,533
$8,422
$9,362
hepatocellular
carcinoma (b)
Cost of treating liver
$86,552
$98,265
$111,432
transplant (b)
Wages and benefits
$445,000
$467,220
$488,315
Gross revenue
1,100,450
1,321,480
1,492,112
Expenses(a)
$1,047.7
$1,209.23
$1,404.28
Net profit(a)
$654,402.3
$853,050.77
$1002,392.8
The annual cost of treating one case of detected chronic hepatitis B including the test and
physician time is estimated at $1047.7. Whereas, if no screening occurred, an asymptomatic
patient could progress to decompensated cirrhosis, hepatocellular carcinoma which is
estimated at $11,459 and $7,533 respectively.
Option (a) is what this project is recommending, and the cost estimated here is per 1 case of
detected chronic hepatitis B.
Option (b) is the cost of treating complications from undetected chronic hepatitis B per case.
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